Status: Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
Participants needed: 800
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: AstraZenecaUpdated: Jun 10, 2026Locations: 317
Eligibility criteria
Histologically confirmed diagnosis of endometrial carcinoma or carcinosarcoma. [+4]
Had uterine sarcomas or uterine neuroendocrine carcinoma. [+6]